Jason Kellogg, MD
Psychiatry · Irvine, CANPI 1952331530
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,096,405 of the $2,722,584 with a category attached, or 77.0%. It is spread thinly across 32 manufacturers, the largest accounting for just 21.4%. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,397 payments — averaging $801.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$583K
- Neurocrine Biosciences, Inc.$577K
- Acadia Pharmaceuticals Inc$407K
- Teva Pharmaceuticals USA, Inc.$242K
- Otsuka America Pharmaceutical, Inc.$214K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$197K
- plus $502K from 26 others
Across 169 payments — averaging $1907.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$167K
- Neurocrine Biosciences, Inc.$88K
- AbbVie$51K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
- Eli Lilly$2K
- Genentech, Inc.$1K
What the payments were for
- Consulting fees$211,2708%
- Speaking & faculty fees$2,096,40577%
- Travel & lodging$348,96513%
- Food & beverage$65,8982%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$567,954
- NUPLAZID$386,619
- INVEGA SUSTENNA$329,419
- INVEGA TRINZA$325,907
- ARISTADA$291,504
- SPRAVATO$247,333
- REXULTI$197,625
- CAPLYTA$194,945
- AUSTEDO$182,386
- Fanapt$116,459
- COBENFY$83,994
- ARISTADA INITIO$72,876
- LYBALVI$70,972
- VRAYLAR$69,246
- LATUDA$36,199
- PERSERIS$35,870
- Austedo XR$35,150
- UZEDY$20,032
- ABILIFY MAINTENA$11,335
- ZULRESSO$6,672
How this compares
$2,722,584 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 24 | $15,708 |
| TrintellixVortioxetine Hydrobromide | 34 | $12,499 |
| Divalproex Sodium | 120 | $4,611 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $4,189 |
| Aripiprazole | 23 | $3,163 |
| Olanzapine | 40 | $2,721 |
| Quetiapine Fumarate | 67 | $1,810 |
| Memantine Hcl | 66 | $1,369 |
| Mirtazapine | 52 | $800 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $769 |
| Topiramate | 26 | $664 |
| Buspirone Hcl | 34 | $585 |
| Trazodone Hcl | 89 | $516 |
| Sertraline Hcl | 46 | $432 |
| Duloxetine Hcl | 33 | $432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,503 | $12,49934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Irvine
- Charles Tuan-Tu NguyenIrvine$2.1M
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jonathan MeyerSan Diego$2.3M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
- Jason BermakSan Rafael$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.